SPL · ASX

Starpharma Holdings Limited (ASX:SPL)

AU$0.09

 -0.003 (-3.226%)
ASX:Live
09/05/2025 03:40:53 PM
Hammer Bullish HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

SPL Overview

SPL Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About SPL

Website

Starpharma Holdings Limited

Telephone

61.3.8532.2700

Address

4-6 Southampton Crescent Abbotsford, Victoria (VIC) 3067

Description

Starpharma Holdings Ltd. engages in the research, development, and commercialization of dendrimer products for pharmaceutical and healthcare applications. Its pipeline and products include SN38, cabazitaxel, docetaxel, radiopharmaceuticals, antibody-drug conjugates, and anti-infective products. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

SPL Price Chart

Key Stats

Market Cap

AU$39.73M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.09 - 0.13

Trade Value (12mth)

AU$11,826.00

1 week

1.09%

1 month

-3.12%

YTD

-15.45%

1 year

-25.6%

All time high

2.52

Key Fundamentals

EPS 3 yr Growth

-60.20%

EBITDA Margin

-169.40%

Operating Cashflow

-$7m

Free Cash Flow Return

-20.60%

ROIC

-24.10%

Interest Coverage

N/A

Quick Ratio

4.60

Other Data

Shares on Issue (Fully Dilluted)

416m

HALO Sector

Healthcare

Next Company Report Date

20-Aug-25

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.15

SPL Announcements

Latest Announcements

Date Announcements

30 April 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

04 April 25

Application for quotation of securities - SPL

×

Application for quotation of securities - SPL

04 April 25

Notification of cessation of securities - SPL

×

Notification of cessation of securities - SPL

17 March 25

Becoming a substantial holder

×

Becoming a substantial holder

26 February 25

Half Yearly Report and Accounts

×

Half Yearly Report and Accounts

29 January 25

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

16 January 25

DEP Presentation at Targeted Radio Therapies Conference

×

DEP Presentation at Targeted Radio Therapies Conference

19 December 24

SPL receives positive FDA feedback on DEP SN38 for PROC

×

SPL receives positive FDA feedback on DEP SN38 for PROC

12 December 24

Notification regarding unquoted securities - SPL

×

Notification regarding unquoted securities - SPL

12 December 24

Change of Director's Interest Notice - Ms Cheryl Maley

×

Change of Director's Interest Notice - Ms Cheryl Maley

04 December 24

DEP Presentation at Radiopharmaceuticals Summit

×

DEP Presentation at Radiopharmaceuticals Summit

29 November 24

Results of 2024 Reconvened Annual General Meeting

×

Results of 2024 Reconvened Annual General Meeting

27 November 24

AGM Notice of Reconvened Meeting

×

AGM Notice of Reconvened Meeting

26 November 24

AGM Chair's address and CEO's presentation

×

AGM Chair's address and CEO's presentation

26 November 24

Results of 2024 Annual General Meeting

×

Results of 2024 Annual General Meeting

21 November 24

DEP SN38 Results Showcased at GI Cancer Conference

×

DEP SN38 Results Showcased at GI Cancer Conference

18 November 24

Bell Potter Healthcare Conference Presentation

×

Bell Potter Healthcare Conference Presentation

06 November 24

Change of Director's Interest Notice

×

Change of Director's Interest Notice

01 November 24

Notification regarding unquoted securities - SPL

×

Notification regarding unquoted securities - SPL

31 October 24

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

29 October 24

Australian Microcap Conference Presentation

×

Australian Microcap Conference Presentation

28 October 24

Notice of Annual General Meeting/Proxy Form

×

Notice of Annual General Meeting/Proxy Form

25 October 24

Application for quotation of securities - SPL

×

Application for quotation of securities - SPL

24 October 24

Change of Director's Interest Notice - R Thomas

×

Change of Director's Interest Notice - R Thomas

18 October 24

SPL7013 Nasal Spray Australia Update

×

SPL7013 Nasal Spray Australia Update

SPL Fundamentals

Per Share Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.04 -0.04 -0.02 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.04 -0.04 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 20.1 3.8 48.2 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.03 -0.01 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.03 -0.03 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 9.2 4.6 55.6 Lock Lock Lock
     Yield % Lock Lock Lock Lock -4.6 -11.2 -18.1 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.12 0.08 0.07 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.12 0.08 0.07 Lock Lock Lock
     Growth % Lock Lock Lock Lock -22.8 -28.4 -19.6 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 407 409 411 Lock Lock Lock
Basic m Lock Lock Lock Lock 407 409 411 Lock Lock Lock

Financial Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales $m Lock Lock Lock Lock 5 3 8 Lock Lock Lock
     Growth % Lock Lock Lock Lock 160.4 -37.2 182.0 Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 26 26 22 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock 2 1 7 Lock Lock Lock
     Growth % Lock Lock Lock Lock 253.3 -35.9 480.7 Lock Lock Lock
     Margin % Lock Lock Lock Lock 40.7 41.6 85.6 Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 59 58 14 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -23 -23 -14 Lock Lock Lock
     Growth % Lock Lock Lock Lock 17.7 -2.9 40.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock -487.3 -798.9 -169.4 Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -24 -25 -15 Lock Lock Lock
     Growth % Lock Lock Lock Lock 16.7 -3.3 38.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -510.4 -839.5 -182.9 Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -23 -23 -14 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock -7 -8 -6 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -16 -16 -8 Lock Lock Lock
     Growth % Lock Lock Lock Lock 18.1 3.2 47.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -345.0 -532.1 -98.5 Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -13 -14 -7 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 1 1 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock -1 -1 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 3 -1 -5 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -14 -14 -7 Lock Lock Lock
     Growth % Lock Lock Lock Lock 7.0 -1.1 50.1 Lock Lock Lock
     Margin % Lock Lock Lock Lock -3.0 -4.8 -0.9 Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 50 35 23 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 66 52 37 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 7 3 2 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -42 -27 -20 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 18 17 9 Lock Lock Lock
Equity $m Lock Lock Lock Lock 48 35 28 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 56 38 30 Lock Lock Lock
     Growth % Lock Lock Lock Lock -11.0 -32.8 -19.9 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -24.4 -30.0 -22.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -33.4 -44.9 -29.0 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -39.8 -49.5 -40.6 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -27.2 -33.5 -24.1 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -22.2 -29.0 -20.6 Lock Lock Lock

Ratios Records

Historical data

Forecast data

AUD 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 1.8 1.1 1.4 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -86.2 -77.3 -70.5 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 5.9 3.3 4.9 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 5.7 3.1 4.6 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 82.3 74.7 71.0 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -128.6 -93.5 -104.7 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.6 0.4 1.1 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 1.2 0.6 0.5 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.1 0.1 0.3 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 144.4 225.1 32.9 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.1 0.1 0.2 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.1 0.1 0.2 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -500.1 -791.7 -165.2 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -35.4 -44.7 -37.2 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -24.4 -30.0 -22.2 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.4 1.5 1.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -33.4 -44.9 -29.0 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -33.4 -44.9 -29.0 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 298.8 595.1 794.9 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 634.4 997.9 320.9 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 933.2 1,593.0 1,115.8 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 633.9 1,465.9 2,066.8 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 299.3 127.2 -951.0 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.15%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

SPL Shortsell

Frequently Asked Questions

The current share price of Starpharma Holdings Limited (SPL:ASX) is AU$0.09.
The 52-week high share price for Starpharma Holdings Limited (SPL:ASX) is AU$0.13.
The 52-week low share price for Starpharma Holdings Limited (SPL:ASX)? is AU$0.09.
Starpharma Holdings Limited (SPL:ASX) does not pay a dividend.
Starpharma Holdings Limited (SPL:ASX) does not pay a dividend.
Starpharma Holdings Limited (SPL:ASX) has a franking level of 0.0%.
Starpharma Holdings Limited (SPL:ASX) is classified in the Healthcare.
The current P/E ratio for Starpharma Holdings Limited (SPL:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.